INDEXES OF SEVERITY OF OBSTRUCTIVE SLEEP-APNEA SYNDROME DO NOT CHANGE DURING MEDROXYPROGESTERONE ACETATE THERAPY
INDEXES OF SEVERITY OF OBSTRUCTIVE SLEEP-APNEA SYNDROME DO NOT CHANGE DURING MEDROXYPROGESTERONE ACETATE THERAPY
复制标题
DOI：
10.1378/chest.96.2.262
复制
发表时间：
1989-08-01
期刊：
影响因子：
9.6
通讯作者：
WOOTEN, SA
中科院分区：
文献类型：
--
作者：
COOK, WR;BENICH, JJ;WOOTEN, SA
醋酸甲羟孕酮（MPA）可通过改变咽肌相对于膈肌和肋间肌的功能，改变阻塞性睡眠呼吸暂停（OSA）综合征患者呼吸紊乱事件（DBE）的频率和/或持续时间。10例OSA综合征男性患者接受了初始多导睡眠图，监测EEG、EOG、肌舌骨肌EMG、口腔和鼻腔气流、腹部和胸部运动以及SaO 2。然后患者进入一项随机、双盲交叉研究，使用MPA 150 mg/天和MPA安慰剂。每位患者服用一周的药片，然后进行第二次多导睡眠图。在三周洗脱后，患者在第三次也是最后一次睡眠研究之前再次服用片剂一周。药物和安慰剂之间的DBE时间（表示为睡眠时间的百分比），DBE频率，DBE平均持续时间或DBE期间O2饱和度的平均下降无显著差异。我们的结论是，MPA治疗不会改变OSA综合征的严重程度指数。
Medroxyprogesterone acetate (MPA) could change the frequency and/or duration of disordered breathing events (DBEs) in patients with the obstructive sleep apnea (OSA) syndrome by altering pharyngeal muscle function relative to diaphragm and external intercostal function. Ten male patients with OSA syndrome underwent an initial polysomnogram with monitoring of EEG, EOG, myohyoid EMG, oral and nasal airflow, abdominal and thoracic movement, and SaO2. The patients were then entered into a randomized, double-blind crossover study using MPA, 150 mg/day, and MPA placebo. Each patient took tablets for one week and then had a second polysomnogram. After a three week washout, the patient again took tablets for a week prior to the third and final sleep study. There was no significant difference between drug and placebo for DBE time (expressed as a percentage of sleep time), DBE frequency, DBE mean duration or mean fall in O2 saturation during DBEs. We conclude that treatment with MPA does not alter indices of severity of the OSA syndrome.